← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS › Lincosamides
lincomycin
J01FF02
Forms & Strengths
- Injectable solution: 300 mg/mL (2 mL and 10 mL vials)
Adult Dosing
- Serious infections: 600 mg IM every 12 to 24 hours
- Severe infections: 600 mg to 1 g IV every 8 to 12 hours infused over at least 1 hour
- Maximum daily dose: 8 g IV
Pediatric Dosing
- Infants > 1 month and children - Serious infections: 10 mg/kg IM every 12 to 24 hours
- Infants > 1 month and children - Severe infections: 10 mg/kg to 20 mg/kg/day IV divided into 2 or 3 equal doses
- Safety and efficacy in infants under 1 month not established
Indications
- Treatment of serious infections caused by susceptible strains of gram-positive aerobes (streptococci, pneumococci, staphylococci)
- Alternative to penicillin when penicillin is contraindicated
Mechanism of Action
- Lincosamide antibiotic that binds exclusively to the 50S ribosomal subunit of susceptible bacteria
- Inhibits protein synthesis early in the elongation phase
- Bacteriostatic or bactericidal action depending on drug concentration and organism susceptibility
Contraindications
- Hypersensitivity to lincomycin or clindamycin
- Treatment of minor bacterial infections or viral infections
- Pre-existing severe diarrhea or pseudomembranous colitis history
Adverse Reactions
- Clostridioides difficile-associated diarrhea (CDAD) / pseudomembranous colitis
- Nausea, vomiting, glossitis, stomatitis, abdominal pain
- Maculopapular rash, urticaria, vaginitis
- Neutropenia, leukopenia, agranulocytosis, thrombocytopenic purpura
- Hypotension and syncope with rapid intravenous administration
- Pain, induration, and sterile abscess formation at IM injection sites
Drug Interactions
- Neuromuscular blocking agents: Enhances neuromuscular blockade, potentially leading to respiratory depression
- Erythromycin: Antagonistic effect observed in vitro due to competitive binding at the 50S ribosomal subunit
- Kaolin-pectin mixtures: Decreases absorption of oral lincomycin (though oral forms are not standard, relevant for combination)
Curated Content: Needs Vetting Before Put to Clinical Use